{"id":"https://openalex.org/W4417019136","doi":"https://doi.org/10.1182/blood-2025-2319","title":"Overcoming CAR T cell resistance in NPM1c and KMT2Ar AML through menin pathway inhibition","display_name":"Overcoming CAR T cell resistance in NPM1c and KMT2Ar AML through menin pathway inhibition","publication_year":2025,"publication_date":"2025-11-03","ids":{"openalex":"https://openalex.org/W4417019136","doi":"https://doi.org/10.1182/blood-2025-2319"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2025-2319","doi":"https://doi.org/10.1182/blood-2025-2319","is_oa":true,"landing_page_url":"https://doi.org/10.1182/blood-2025-2319","pdf_url":"https://ashpublications.org/blood/article-pdf/146/Supplement 1/2319/2448051/blood-5066-main.pdf","source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ashpublications.org/blood/article-pdf/146/Supplement 1/2319/2448051/blood-5066-main.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050917506","display_name":"Sara Piccinelli","orcid":"https://orcid.org/0000-0001-8998-4867","observed_orcids":["https://orcid.org/0000-0001-8998-4867"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara Piccinelli","raw_affiliation_strings":["1Dana Farber Cancer Institute, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana Farber Cancer Institute, Boston, United States","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029479702","display_name":"Wallace Bourgeois","orcid":"https://orcid.org/0000-0002-6935-8890","observed_orcids":["https://orcid.org/0000-0002-6935-8890"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wallace Bourgeois","raw_affiliation_strings":["1Dana Farber Cancer Institute, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana Farber Cancer Institute, Boston, United States","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089239728","display_name":"Andreia Maia","orcid":"https://orcid.org/0000-0002-7860-6219","observed_orcids":["https://orcid.org/0000-0002-7860-6219"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andreia Maia","raw_affiliation_strings":["1Dana Farber Cancer Institute, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana Farber Cancer Institute, Boston, United States","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5094219048","display_name":"Eden Bobilev","orcid":"https://orcid.org/0009-0005-0492-3608","observed_orcids":["https://orcid.org/0009-0005-0492-3608"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eden Bobilev","raw_affiliation_strings":["1Dana Farber Cancer Institute, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana Farber Cancer Institute, Boston, United States","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5128825013","display_name":"Fuguo Liu","orcid":"https://orcid.org/0009-0005-2850-4184","observed_orcids":["https://orcid.org/0009-0005-2850-4184"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fuguo Liu","raw_affiliation_strings":["1Dana Farber Cancer Institute, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana Farber Cancer Institute, Boston, United States","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042549611","display_name":"Xingyu Deng","orcid":"https://orcid.org/0009-0000-3878-5438","observed_orcids":["https://orcid.org/0009-0000-3878-5438","https://orcid.org/0009-0008-5447-2560"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xingyu Deng","raw_affiliation_strings":["1Dana Farber Cancer Institute, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana Farber Cancer Institute, Boston, United States","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101990373","display_name":"Han Dong","orcid":"https://orcid.org/0009-0003-4975-8269","observed_orcids":["https://orcid.org/0009-0003-4975-8269"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Han Dong","raw_affiliation_strings":["1Dana Farber Cancer Institute, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana Farber Cancer Institute, Boston, United States","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068050082","display_name":"Robert J. Soiffer","orcid":"https://orcid.org/0000-0002-5810-1192","observed_orcids":["https://orcid.org/0000-0002-5810-1192"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Soiffer","raw_affiliation_strings":["1Dana Farber Cancer Institute, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana Farber Cancer Institute, Boston, United States","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047701430","display_name":"Catherine J. Wu","orcid":"https://orcid.org/0000-0002-3348-5054","observed_orcids":["https://orcid.org/0000-0002-3348-5054"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Catherine Wu","raw_affiliation_strings":["1Dana Farber Cancer Institute, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana Farber Cancer Institute, Boston, United States","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008718116","display_name":"Jerome Ritz","orcid":"https://orcid.org/0000-0001-5526-4669","observed_orcids":["https://orcid.org/0000-0001-5526-4669"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jerome Ritz","raw_affiliation_strings":["1Dana Farber Cancer Institute, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana Farber Cancer Institute, Boston, United States","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082924494","display_name":"Daniel J. DeAngelo","orcid":"https://orcid.org/0000-0001-7865-2306","observed_orcids":["https://orcid.org/0000-0001-7865-2306"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Deangelo","raw_affiliation_strings":["1Dana Farber Cancer Institute, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana Farber Cancer Institute, Boston, United States","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069401963","display_name":"Andrew A. Lane","orcid":"https://orcid.org/0000-0001-7380-0226","observed_orcids":["https://orcid.org/0000-0001-7380-0226"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Lane","raw_affiliation_strings":["1Dana Farber Cancer Institute, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana Farber Cancer Institute, Boston, United States","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014845006","display_name":"Roman M. Shapiro","orcid":"https://orcid.org/0000-0002-7622-8322","observed_orcids":["https://orcid.org/0000-0002-7622-8322"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roman Shapiro","raw_affiliation_strings":["1Dana Farber Cancer Institute, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana Farber Cancer Institute, Boston, United States","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045082338","display_name":"Jianzhu Chen","orcid":"https://orcid.org/0000-0002-5687-6154","observed_orcids":["https://orcid.org/0000-0002-5687-6154"]},"institutions":[{"id":"https://openalex.org/I63966007","display_name":"Massachusetts Institute of Technology","ror":"https://ror.org/042nb2s44","country_code":"US","type":"education","lineage":["https://openalex.org/I63966007"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jianzhu Chen","raw_affiliation_strings":["2Massachusetts Institute of Technology, Cambridge, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Massachusetts Institute of Technology, Cambridge, United States","institution_ids":["https://openalex.org/I63966007"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029390145","display_name":"John Koreth","orcid":"https://orcid.org/0000-0002-7428-1330","observed_orcids":["https://orcid.org/0000-0002-7428-1330"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Koreth","raw_affiliation_strings":["1Dana Farber Cancer Institute, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana Farber Cancer Institute, Boston, United States","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5061484901","display_name":"Rizwan Romee","orcid":"https://orcid.org/0000-0001-9077-4736","observed_orcids":["https://orcid.org/0000-0001-9077-4736"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rizwan Romee","raw_affiliation_strings":["1Dana Farber Cancer Institute, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana Farber Cancer Institute, Boston, United States","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"146","issue":"Supplement 1","first_page":"2319","last_page":"2319"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.5938000082969666,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.5938000082969666,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.3644999861717224,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.005900000222027302,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9710000157356262},{"id":"https://openalex.org/keywords/revumenib","display_name":"revumenib","score":0.9729999899864197},{"id":"https://openalex.org/keywords/men1-mutation","display_name":"MEN1 gene mutation","score":0.5820000171661377},{"id":"https://openalex.org/keywords/car-t-cell-resistance","display_name":"CAR T-cell resistance","score":0.8349999785423279},{"id":"https://openalex.org/keywords/mhc-class-i-expression","display_name":"MHC class I expression","score":0.7080000042915344},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.4830000102519989},{"id":"https://openalex.org/keywords/relapse-prevention","display_name":"relapse prevention","score":0.44699999690055847},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.33399999141693115}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.7595999836921692},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5357000231742859},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.46889999508857727},{"id":"https://openalex.org/C553184892","wikidata":"https://www.wikidata.org/wiki/Q1141429","display_name":"Flow cytometry","level":2,"score":0.45890000462532043},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.453900009393692},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.43650001287460327},{"id":"https://openalex.org/C2483381","wikidata":"https://www.wikidata.org/wiki/Q18030194","display_name":"NPM1","level":5,"score":0.41999998688697815},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.4129999876022339},{"id":"https://openalex.org/C2779469564","wikidata":"https://www.wikidata.org/wiki/Q1920577","display_name":"MEN1","level":4,"score":0.41260001063346863},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.41019999980926514},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.4025000035762787},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3937000036239624},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.39259999990463257},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.3549000024795532},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.3506999909877777},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.3382999897003174},{"id":"https://openalex.org/C174510640","wikidata":"https://www.wikidata.org/wiki/Q489618","display_name":"HEK 293 cells","level":3,"score":0.3357999920845032},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3314000070095062},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.3287999927997589},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.322299987077713},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.3208000063896179},{"id":"https://openalex.org/C148125776","wikidata":"https://www.wikidata.org/wiki/Q1622348","display_name":"CD28","level":4,"score":0.3100000023841858},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.30469998717308044},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.301800012588501},{"id":"https://openalex.org/C79484868","wikidata":"https://www.wikidata.org/wiki/Q5971673","display_name":"IL-2 receptor","level":4,"score":0.3009999990463257},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.30090001225471497},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.2994999885559082},{"id":"https://openalex.org/C1009742","wikidata":"https://www.wikidata.org/wiki/Q5333998","display_name":"Ectodomain","level":3,"score":0.296099990606308},{"id":"https://openalex.org/C2777933648","wikidata":"https://www.wikidata.org/wiki/Q21114866","display_name":"SOX2","level":4,"score":0.2825999855995178},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2678000032901764},{"id":"https://openalex.org/C2778957590","wikidata":"https://www.wikidata.org/wiki/Q798033","display_name":"CD19","level":3,"score":0.26759999990463257},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.25600001215934753},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.2508000135421753},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.2508000135421753},{"id":"https://openalex.org/C51785407","wikidata":"https://www.wikidata.org/wiki/Q2627568","display_name":"Effector","level":2,"score":0.25060001015663147}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2025-2319","doi":"https://doi.org/10.1182/blood-2025-2319","is_oa":true,"landing_page_url":"https://doi.org/10.1182/blood-2025-2319","pdf_url":"https://ashpublications.org/blood/article-pdf/146/Supplement 1/2319/2448051/blood-5066-main.pdf","source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1182/blood-2025-2319","doi":"https://doi.org/10.1182/blood-2025-2319","is_oa":true,"landing_page_url":"https://doi.org/10.1182/blood-2025-2319","pdf_url":"https://ashpublications.org/blood/article-pdf/146/Supplement 1/2319/2448051/blood-5066-main.pdf","source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4417019136.pdf"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4417007003","https://openalex.org/W7129764724","https://openalex.org/W7204215927","https://openalex.org/W7212419680","https://openalex.org/W4412001415","https://openalex.org/W7222965131","https://openalex.org/W7221095447","https://openalex.org/W4206996392","https://openalex.org/W7162548224","https://openalex.org/W4413373485"],"abstract_inverted_index":{"Abstract":[0],"Background.":[1],"Acute":[2],"myeloid":[3],"leukemia":[4],"(AML)":[5],"remains":[6],"a":[7,75,86,290,437,509,607],"clinical":[8,60,641],"challenge":[9],"due":[10],"to":[11,217,379,405,434,482,537,616],"high":[12],"relapse":[13],"rates":[14],"and":[15,38,85,117,167,195,204,209,222,228,235,246,315,329,366,475,498,515,597,622],"limited":[16],"durable":[17],"treatment":[18],"options,":[19],"especially":[20],"in":[21,32,62,193,196,220,250,354,600,631,647],"older":[22],"or":[23,106,262,266,307,348,651],"unfit":[24],"patients.":[25],"Among":[26],"the":[27,81,93,119,137,149,155,309,360,370,421,553,583,618],"most":[28],"frequent":[29],"genetic":[30],"alterations":[31],"AML":[33,99,199,372,601,634],"are":[34,45,544],"NPM1":[35,365],"mutations":[36],"(NPM1c)":[37],"KMT2A/MLL":[39],"rearrangements":[40],"(KMT2Ar),":[41],"both":[42,445],"of":[43,96,121,157,180,293,311,337,362,423,454,485,512,593,620,643],"which":[44],"highly":[46],"dependent":[47],"on":[48,98,282,300],"menin":[49,55,111,186,455,614],"for":[50,161,192,416],"inducing":[51],"leukemogenesis.":[52],"While":[53],"small-molecule":[54],"inhibitors":[56],"have":[57],"shown":[58],"early":[59,554],"promise":[61],"these":[63],"subtypes,":[64],"resistance\u2014particularly":[65],"via":[66,176,225],"MEN1":[67,268,352],"mutations\u2014limits":[68],"their":[69],"long-term":[70],"efficacy.":[71],"We":[72,101],"previously":[73,132],"developed":[74,153],"TCR-mimetic":[76,134],"CAR":[77,88,125,151,171,294,312,325,343,447,555,624],"T":[78,89,108,126,172,183,295,313,326,344,355,368,391,425,448,471,530,539,550,556,563,625],"cell":[79,90,200,206,305,327,345,373,392,449,557],"targeting":[80,136],"NPM1c-derived":[82],"neoepitope":[83],"(AIQ)":[84],"CD70-specific":[87,623],"that":[91,103,612],"leverages":[92,613],"restricted":[94],"expression":[95,224,353,599],"CD70":[97,150,223,598],"blasts.":[100],"hypothesized":[102],"combining":[104],"NPM1-CAR":[105,390],"CD70-CAR":[107,367,424,529,538],"cells":[109,127,173,287,296,314,426,472,518,531,540,551,564,626],"with":[110,215,234,257,400,469,528,577,582,649],"inhibition":[112,615],"could":[113],"enhance":[114],"anti-leukemic":[115,579],"efficacy":[116,245,450,619],"suppress":[118],"emergence":[120],"resistance.":[122],"Methods.":[123],"NPM1c-specific":[124],"were":[128,174,213,232,248,272,331],"generated":[129,175],"using":[130,154],"our":[131],"published":[133],"construct":[135],"AIQ":[138],"neoepitope-HLA-A2":[139],"complex":[140],"(Xie":[141],"et":[142],"al.,":[143],"Nat":[144],"Biomed":[145],"Eng,":[146],"2022),":[147],"while":[148,561,627],"was":[152,190,451,473],"ectodomain":[156],"CD27":[158],"(the":[159],"ligand":[160],"CD70).":[162],"Both":[163],"constructs":[164],"incorporated":[165],"4-1BB":[166],"CD3\u03b6":[168],"signaling":[169],"domains.":[170],"VSVG":[177],"lentiviral":[178],"transduction":[179],"healthy":[181],"donor":[182],"cells.":[184,356,602],"The":[185],"inhibitor":[187],"revumenib":[188,216,237,278,316,339,363,413,465,533],"(SNDX-5613)":[189],"used":[191],"vitro":[194],"vivo":[197,244],"experiments.":[198],"lines\u2014including":[201],"NPM1-mutant":[202,259,462,650],"OCI-AML3":[203,395],"KMT2Ar":[205,652],"lines":[207,374],"MV4;11":[208,264,428,514,517],"MOLM13\u2014or":[210],"PDX":[211,261,463],"samples":[212],"cultured":[214],"assess":[218,380],"changes":[219],"MHC-I":[221],"flow":[226],"cytometry":[227],"RNA-seq.":[229],"Cytotoxicity":[230],"assays":[231],"performed":[233],"without":[236,267],"across":[238,396],"multiple":[239],"effector:target":[240],"(E:T)":[241],"ratios.":[242],"In":[243,444,458,504],"safety":[247],"evaluated":[249,359],"NOD":[251],"Scid":[252],"Gamma":[253],"(NSG)":[254],"mice":[255,460,507],"engrafted":[256],"either":[258],"HLA-A2\u207a":[260],"luciferase-recombinant":[263],"(with":[265],"mutant":[269],"mix).":[270],"Mice":[271],"treated":[273,527],"with:":[274],"(a)":[275],"vehicle,":[276],"(b)":[277],"chow":[279],"(0.033\u20130.1%":[280],"starting":[281],"day":[283,301],"4":[284,302,386,417],"after":[285,303],"tumor":[286,304,524],"injection),":[288,306],"(c)":[289],"single":[291],"dose":[292],"(5\u20137":[297],"\u00d7":[298],"10\u2076":[299],"(d)":[308],"combination":[310,361,584,610],"chow.":[317],"Tumor":[318],"burden":[319],"(BLI),":[320],"circulating":[321],"blasts":[322],"(flow":[323],"cytometry),":[324],"persistence,":[328],"survival":[330,477,484],"monitored.":[332],"Results.":[333],"After":[334],"5":[335],"days":[336,500],"incubation,":[338],"did":[340],"not":[341],"impair":[342],"viability,":[346],"proliferation,":[347],"IFN-\u03b3":[349],"secretion,":[350],"despite":[351],"Next,":[357],"we":[358],"plus":[364,532],"against":[369,394,427],"above-mentioned":[371],"at":[375,407,436,568],"different":[376],"E:T":[377,398,439],"ratios":[378],"killing":[381],"capacity.":[382],"Revumenib":[383],"(250":[384],"nM,":[385],"days)":[387,418],"significantly":[388,419,522],"augmented":[389],"cytotoxicity":[393,422],"all":[397],"ratios,":[399],"lysis":[401,431],"increasing":[402,430],"from":[403,432],"41%":[404],"96%":[406],"5:1":[408],"(p":[409,441],"<":[410,442,490,496],"0.05).":[411,443,503],"Similarly,":[412],"(50":[414],"nM":[415],"enhanced":[420,578],"cells,":[429],"18%":[433],"65%":[435],"0.5:1":[438],"ratio":[440],"cases,":[446],"maintained":[452],"regardless":[453],"mutation":[456],"status.":[457],"NSG":[459,506],"bearing":[461,508],"AML,":[464],"(0.033%":[466,534],"chow)":[467],"combined":[468],"NPM1c-CAR":[470],"safe":[474],"extended":[476],"beyond":[478],"160":[479],"days,":[480],"compared":[481],"median":[483],"28":[486],"(PDX":[487],"alone,":[488],"p":[489,495],"0.05),":[491,497],"54":[492],"(CAR":[493],"T,":[494],"84":[499],"(revumenib,":[501],"p<":[502],"parallel,":[505],"mixed":[510],"population":[511],"luciferase+":[513],"MEN1-mutant":[516],"(80:20":[519],"ratio)":[520],"exhibited":[521],"improved":[523],"control":[525],"when":[526],"chow),":[535],"relative":[536],"alone.":[541],"Survival":[542],"outcomes":[543],"currently":[545],"being":[546],"evaluated.":[547],"Notably,":[548],"CD8\u207a":[549],"dominated":[552],"response":[558],"(day":[559,571],"14),":[560],"CD4\u207a":[562],"became":[565],"more":[566],"prominent":[567],"later":[569],"stages":[570],"70).":[572],"This":[573],"temporal":[574],"shift,":[575],"along":[576],"activity":[580],"observed":[581],"therapies,":[585],"may":[586],"be":[587],"partly":[588],"explained":[589],"by":[590],"revumenib-induced":[591],"upregulation":[592],"HLA":[594],"class":[595],"I":[596],"Conclusions.":[603],"These":[604],"findings":[605],"highlight":[606],"novel,":[608],"rational":[609],"strategy":[611],"potentiate":[617],"NPM1c-":[621],"simultaneously":[628],"overcoming":[629],"resistance":[630],"genetically":[632],"defined":[633],"subtypes.":[635],"Our":[636],"preclinical":[637],"data":[638],"strongly":[639],"support":[640],"translation":[642],"this":[644],"approach,":[645],"particularly":[646],"patients":[648],"AML.":[653]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2025-12-05T00:00:00"}